Credit: Shutterstock photoUroGen Pharma, which is developing formulations of a chemotherapy to treat urological cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The Ra'anana, Israel-based company was founded in 2004 and plans to list on the Nasdaq under the symbol URGN. UroGen Pharma filed confidentially on March 4, 2016. Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Urological cancer biotech UroGen Pharma files for a $50 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
